Invivo Therapeutics (NVIV) Announces Proposed Public Offering of Common Stock

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

The shares described above will be offered pursuant to a shelf registration statement on Form S-3 (No. 333-234353) that was previously filed with and declared effective by the Securities and Exchange Commission, or the SEC, on November 14, 2019.

You May Also Be Interested In

• Viking Therapeutics raises $575M through stock and note offerings
• Bluerock Acquisition Corp. II closes $172.5M IPO on Nasdaq
• BRC Group Holdings to acquire Sangoma Technologies for ~$204M